Articles:
Publications:

an hour ago

Clinical Trial for Bundibugyo Ebola Treatments Starts

Clinical Trial for Bundibugyo Ebola Treatments Starts

A new clinical trial aimed at identifying a safe and effective treatment against the virus behind the growing Ebola outbreak in Africa began on July 2. The trial is assessing a monoclonal antibody and an antiviral medication, both developed by... Read more.

More on this topic

KRWG - New Mexico 3 hours ago
Turn on Transparency.
Ebola treatment trials begin
Owner: New Mexico State University More info
BBC 10 minutes ago
Turn on Transparency.
Ebola treatments trial begins in the Democratic Republic of Congo
Owner: British Government through Ofcom More info
The Epoch Times an hour ago
Turn on Transparency.
Clinical Trial for Bundibugyo Ebola Treatments Starts
Owner: John Tang More info
More

More from The Epoch Times

The Epoch Times 3 hours ago
Turn on Transparency.
Newsom Partners with Anthropic to Allow California Government Use of Claude at Half Price
Owner: John Tang More info
The Epoch Times an hour ago
Turn on Transparency.
Clinical Trial for Bundibugyo Ebola Treatments Starts
Owner: John Tang More info
The Epoch Times an hour ago
Turn on Transparency.
Taylor Swift and Travis Kelce May Not Hold Wedding Ceremony at MSG
Owner: John Tang More info
More

Keep exploring Perspectify!

Create a free account and bring
more transparency to your news.

Already have an account? Log in.

Today's Media Watch

Your daily guide to the stories shaping media, journalism, and public trust.

13 hours ago
Tucker Carlson on Life After Fox and the Power of Independent Media
Center-left | Owner: Columbia University Graduate School of Journalism
13 hours ago
The Declaration of Independence Offers a Forgotten Argument for Facts
Neutral | Owner: The Poynter Institute for Media Studies

Learn About Our Fact-Based Transparency System

Our proprietary bias labels help you understand each outlet’s political orientation, editorial independence, and credibility based on factors like ownership, funding, affiliations, content, and media freedom. Learn more in the Perspectify FAQ.

Learn more